1. Introduction {#sec1}
===============

The prevalence of dementia is expected to increase because of a rapidly aging population. Dementia imposes a considerable burden on patients, healthcare providers, and the society \[[@B1]--[@B3]\], unless its onset can be delayed \[[@B4], [@B5]\]. After Alzheimer\'s disease, vascular dementia (VaD) is the most common type of dementia in the world and is mainly caused by hemorrhagic or ischemic cerebrovascular disease. It is characterized by cognitive impairment accompanied by neurodegeneration. It accounts for about 15--20% of dementia cases in North America and Europe \[[@B6]--[@B9]\] and about 30% in Asia and developing countries \[[@B10]--[@B12]\]. Currently, clinical VaD treatment mainly focuses on improving neurological function and blood circulation in the brain \[[@B13], [@B14]\]. The effects of vascular pathology and neurodegeneration on cognitive decline appear to be synergistic \[[@B15]\]; therefore, improving vascular endothelial function and reducing neurodegeneration are necessary for prevention of early VaD. Currently, a successful drug treatment for VaD does not exist \[[@B16], [@B17]\].

Recently, herbal preparations (e.g., Ginkgo extracts and Ginseng products) have been proposed as treatments for memory loss in the elderly \[[@B18]\]. Furthermore, natural products and herbal medicines are widely used for the management and treatment of central nervous system disorders \[[@B14]\]. Herbal medicines are mainly characterized as safe, with few side effects and suitable efficacy. Thus, traditional Chinese medicine (TCM) may have advantages in the treatment of VaD.

In TCM, VaD is thought to be closely associated with the brain and kidney, and its main treatments include tonifying the kidney and essence, activating blood circulation, eliminating phlegm, opening orifices, and removing blood stasis. Currently, however, there is no specific TCM prescription for VaD. Previous studies have indicated that Shenmayizhi formula (SMYZF) could protect nerve cells and preserve vascular endothelial function \[[@B19], [@B20]\]; however, these studies involved limited preclinical observation, and there is a need to verify its efficacy further.

Additionally, many previous studies have reported that Ginkgo extracts could inhibit apoptosis of hippocampal neurons and protect nerves \[[@B21], [@B22]\]. Ginkgo extract tablets have also been reported to increase cerebral blood flow, improve hemodynamics, and protect brain function in patients with VaD \[[@B23]--[@B25]\].

Therefore, in this study, we used Ginkgo extract tablets as the basic treatment drug and used a large sample size to evaluate the clinical efficacy of SMYZF for improving vascular endothelial function and neurological deficits in patients with mild-to-moderate VaD. Specifically, we assessed pre- and posttreatment neuropsychological scale scores and related serum indexes to evaluate the clinical efficacy of SMYZF.

2. Materials and Methods {#sec2}
========================

2.1. Trial Design {#sec2.1}
-----------------

This was a 12-week, randomized, double-blind, controlled trial to evaluate the clinical efficacy of SMYZF combined with Ginkgo extract tablets, which was undertaken in the Community Healthcare Centers of the Jingzhuang town and Shenjiaying, Yanqing District, Beijing, from June 2018 to January 2019. The protocol was approved by the Ethics Committee of Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences (2017XLA033-3). Furthermore, an external data and safety monitoring committee was set up for this study, and the trial was registered with the China Clinical Trials Registry ([ChiCTR1800017359](https://clinicaltrials.gov/ct2/show/ChiCTR1800017359)).

2.2. Participants {#sec2.2}
-----------------

The inclusion criteria were as follows: (1) age between 50 and 85 years; (2) fulfillment of diagnostic criteria for VaD according to the Diagnostic and Statistical Manual of Mental Disorders \[[@B26]\] and the National Institute of Neurological Disorders and Stroke \[[@B27]\]; (3) Clinical Dementia Rating (CDR) score of 1 or 2 (defined as mild-to-moderate cognitive impairment) \[[@B28]\]; (4) Mini-Mental State Examination (MMSE) score of 10--26; (5) Hachinski Ischemic Scale (HIS) score ≥ 7; (6) National Institutes of Health Stroke Scale (NIHSS) score of 5--15; and (7) provision of written informed consent. The exclusion criteria were as follows: (1) HIS score ≤ 6; (2) dementia complicated with depression (reference: Hamilton Depression Scale (HAMD)); (3) CDR score = 3; (4) hemorrhagic or transient cerebral ischemia, severe neurological impairment such as dominant hand hemiplegia, audio-visual impairment, or aphasia, and severe heart, liver, or kidney function impairment; and (5) recent use (within 3 months) of drugs that might affect cognitive function or allergy to the drugs used in this study.

2.3. Randomization and Blinding {#sec2.3}
-------------------------------

The Good Clinical Practice Center of Xiyuan Hospital was responsible for computer generation of the allocation sequence for block randomization of participants. Beijing Kangrentang Pharmaceutical Company prepared and provided the SMYZF granule packages and placebo according to the randomization assignment. All patients were randomly assigned either to the Ginkgo group (*n* = 98) or the SMYZF group (*n* = 98) in a 1 : 1 ratio; all patients in both groups received Ginkgo extract tablets, as well as either placebo or SMYZF granules, respectively. All the collaborating investigators and participants were blinded to the treatment allocation of the patients.

2.4. Intervention {#sec2.4}
-----------------

Patients in both groups took Ginkgo extract tablets (1 tablet, orally, three times daily; obtained from Yangzijiang Pharmaceutical Co., Ltd., Nanjing, China; batch no. 10010321) as a basic treatment. The patients in the SMYZF group took SMYZF granules (4.8 g, orally, twice daily; obtained from Beijing Kangrentang Pharmaceutical Co. Ltd.; Beijing, China), which comprised Radix et Rhizoma Ginseng, Rhizoma Gastrodiae, Ramuli Euonymi, and Rhizoma Chuanxiong. The patients in the Ginkgo group took 4.8 g SMYZF-placebo granules (4.8 g, orally, twice daily; obtained from Beijing Kangrentang Pharmaceutical Co., Ltd.; Beijing, China), which comprised 5% SMYZF granules + 95% dextrin. The taste of the placebo and SMYZF granules was similar. The course of treatment was 12 weeks.

2.5. Serum Analyses {#sec2.5}
-------------------

We obtained blood samples at baseline and at the endpoint. After centrifugation, the upper serum layer was transferred to a disposable EP tube and frozen in a refrigerator at −80°C until required. The serum samples were then thawed at room temperature prior to analysis.

The serum indexes related to vascular endothelial function were determined, which included serum endothelin-1 (ET-1), nitric oxide (NO), vascular endothelial growth factor (VEGF), and von Willebrand factor (vWF). Serum indexes related to neurological function were also determined and included serum neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF), and homocysteine (Hcy). We performed enzyme-linked immunosorbent assays in the laboratory of Xiyuan Hospital to determine ET-1 (KE1362, 96T, ImmunoWay Biotechnology, Plano, TX, USA), VEGF (KE00085, 96T, ProteinTech, Richmond, CA, USA), vWF (ELH-VWF-1, 1*∗*96-VELL, RayBiotech, Peachtree Corners, GA, USA), and BDNF (KE00096, 96T, ProteinTech) serum levels. We used a chemical detection method to assess serum NO (ab65328, 2*∗*96T, Abcam, Cambridge, UK). Serum NSE levels were determined by the electrochemiluminescence method, using the Roche Cobas e601 device (Roche Diagnostics GmbH, Mannheim, Germany) and commercial kits (Cat.12133113122, Roche Diagnostics GmbH). Hcy levels were determined by an enzymatic method using the Roche Cobas e701 device (Roche Diagnostics GmbH, Mannheim, Germany). All the aforementioned protocols were conducted according to the manufacturer\'s instructions.

2.6. Outcomes {#sec2.6}
-------------

The primary outcomes were the neuropsychology scale scores and serum indexes associated with neurological and vascular endothelial function. Specially trained researchers assessed the patients\' pre- and posttreatment MMSE, NIHSS, and Chinese Medicine Symptom Scale (CM-SS) scores. The evaluation criteria for the clinical efficacy rate for the MMSE and NIHSS were as follows: efficacy index = (pretreatment integral − posttreatment integral)/pretreatment score × 100%. An efficacy index ≥85% indicated a control case; from ≥50% to \<85% indicated an obvious effect case; from ≥20% to \<50% indicated an effectiveness case; and \<20% indicated an ineffectiveness case. Deterioration was indicated by an efficacy index \> −20%. Efficacy rate = control + obvious effect + effectiveness \[[@B29]\].

Secondary outcomes were the activities of daily living (ADL) scale scores and the safety indices in the Community Health Service Center of Yanqing, Beijing. Safety outcomes were nausea/vomiting and allergic reactions that disappeared soon after stopping the supplements. Furthermore, we recorded any adverse events during the treatment course.

2.7. Follow-Up {#sec2.7}
--------------

We examined the participants as outpatients every one-and-a-half months. The course of the intervention was 12 weeks. Twenty-four patients dropped out during the study, while 172 patients completed the trial, of which 85 patients were in the SMYZF group and 87 patients in the Ginkgo group.

2.8. Statistical Analysis {#sec2.8}
-------------------------

We included 172 participants who completed the trial in the final analysis. Lilliefors normality test was used to assess whether variables were normally distributed. Normally distributed data were analyzed using the two independent-samples\' Student\'s *t*-test to determine between-group differences and descriptive statistics which were calculated for all variables (mean and SD). Nonnormally distributed data were analyzed using a nonparametric test (Wilcoxon test), and descriptive statistics were calculated as median and interquartile range. We analyzed continuous variables using the chi-square test (*χ*^2^ test) and categorical variables using the ridit test. Statistical significance was set at *P* value \< 0.05. All statistical analyses were performed using SPSS 22 (IBM Corp, GSA ADP, US).

3. Results {#sec3}
==========

3.1. Study Population {#sec3.1}
---------------------

Of the 172 patients with mild-to-moderate VaD from two Community Healthcare Centers, Yanqing District, Beijing, who completed the study from June 2018 to January 2019 ([Figure 1](#fig1){ref-type="fig"}), 85 were males and 87 were females, with ages 50--83 years (mean: 67.65 ± 6.96 years). The Ginkgo group comprised 87 participants (males, 46; females, 41) with a mean age of 68.07 ± 6.83 years; in this group, 13 patients had coronary heart disease, 23 patients had diabetes, and 72 patients had hypertension. The SMYZF group comprised 85 participants (39 males; 46 females) with a mean age of 67.22 ± 7.12 years; in this group, 9 patients had coronary heart disease, 27 patients had diabetes, and 71 patients had hypertension. There were no significant between-group differences in the baseline data (*P* \> 0.05, [Table 1](#tab1){ref-type="table"}).

3.2. Comparison of Posttreatment Curative Effects of the MMSE and NIHSS {#sec3.2}
-----------------------------------------------------------------------

The posttreatment curative effects of improvement in the MMSE scores in the SMYZF and Ginkgo groups were 49.4% and 34.5%, respectively. Furthermore, the curative effects of a decrease in the NIHSS score in the SMYZF and Ginkgo groups were 89.41% and 64.37%, respectively. The posttreatment curative effects were significantly higher in the SMYZF group (*P* \< 0.05), as shown in [Table 2](#tab2){ref-type="table"}.

3.3. Comparison of Cognitive Function and Cognitive Domain in the MMSE {#sec3.3}
----------------------------------------------------------------------

There was a significant posttreatment increase in the MMSE scores in both groups (*P* \< 0.05). There was also a significant posttreatment enhancement in time orientation, immediate memory, delayed recall, retelling, comprehension, attention, and calculation ability in both groups (*P* \< 0.05). The delayed recall, retelling, and comprehension scores increased more significantly in the SMYZF group compared with the Ginkgo group (*P* \< 0.05) ([Table 3](#tab3){ref-type="table"}).

3.4. Between-Group Comparisons of the Pre- and Post-Vascular Endothelial Function {#sec3.4}
---------------------------------------------------------------------------------

There was a significant posttreatment decrease in the serum ET-1 level and an increase in the serum VEGF level in both groups after treatment (*P* \< 0.05). In addition, there was a significant posttreatment increase in the serum NO level and decrease in the serum vWF level in the SMYZF group (*P* \< 0.05). However, the serum ET-1 level decreased, and serum NO level increased more significantly in the SMYZF group compared with the Ginkgo group after treatment (both *P* \< 0.05). There was no between-group difference in the posttreatment improvement in the serum VEGF and vWF levels (all *P* \> 0.05) ([Table 4](#tab4){ref-type="table"}).

3.5. Comparison of Pre- and Posttreatment in the NIHSS and ADL Scores {#sec3.5}
---------------------------------------------------------------------

There was a significant posttreatment decrease in the NIHSS and ADL scores in both groups (*P* \< 0.05, Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Moreover, the posttreatment decrease in the NIHSS scores was greater in the SMYZF group compared with the Ginkgo group (*P* \< 0.05, [Figure 2](#fig2){ref-type="fig"}). There was no significant posttreatment change in the ADL scores in either group (*P* \> 0.05, [Figure 3](#fig3){ref-type="fig"}).

3.6. Serum Indexes Related to Neurological Function {#sec3.6}
---------------------------------------------------

Both groups showed a significant posttreatment decrease in the serum NSE and Hcy levels and an increase in the serum BDNF levels (all *P* \< 0.05). However, the SMYZF group had significantly lower posttreatment serum NSE levels and higher serum BDNF levels than the Ginkgo group (both *P* \< 0.05). There was no significant posttreatment change in the serum Hcy level in either group (both *P* \> 0.05) ([Table 5](#tab5){ref-type="table"}).

3.7. Comparison of Pre- and Posttreatment CM-SS Scores {#sec3.7}
------------------------------------------------------

There was a significant posttreatment decrease in the total CM-SS scores in both groups (both *P* \< 0.05); moreover, the posttreatment total CM-SS scores were lower in the SMYZF group compared with the Ginkgo group. There was a significant posttreatment improvement in single symptoms, including a decline in intelligence, soreness, and weakness of the waist and knees, rigid and silent behavior, cardiopalmus, and tinnitus in both groups (all *P* \< 0.05). Moreover, there was a significant posttreatment improvement in symptoms including restlessness, irritability, cyanosis of the lips, and nocturia in the SMYZF group (all *P* \< 0.05); there was also a posttreatment improvement in the symptoms of spasm and numbness of limbs in the Ginkgo group (both *P* \< 0.05). The SMYZF group showed a significant posttreatment improvement in the symptoms of decline in intelligence, restlessness, irritability, and cyanosis of the lips, as compared with the Ginkgo group (*P* \< 0.05) ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, we investigated the efficacy and safety of using SMYZF granules and Ginkgo extract tablets for the treatment of VaD. We found that SMYZF combined with Ginkgo extract tablets had curative effects on VaD, with improvement of cognitive, vascular endothelial, and neurological function; our findings also demonstrated the safety of this treatment.

VaD is caused by cerebral ischemia and is associated with various vascular risk factors including artery disease, cardiac thrombus embolism, hemodynamic changes, hemorrhage, hematological factors, and diabetes. Subsequently, it causes degeneration and necrosis of neurons and cognitive impairment \[[@B30]\]. Previous studies have reported that VaD treatment is mainly associated with cerebrovascular circulation improvement, increased blood flow, activated brain tissue metabolism, and promotion of neuronal cell functional recovery, thus mitigating dementia symptoms \[[@B31]\]. Previous experimental studies of SMYZF have reported that this herbal formula could reduce neuron damage in the hippocampus \[[@B19]\]. Furthermore, previous clinical studies have reported that SMYZF could improve vascular endothelium function, blood mobility, cerebral blood flow, cognitive function, and memory \[[@B20]\]. These findings, together with our own, demonstrate the efficacy of SMYZF in improving cognitive function in patients with VaD. In TCM, SMYZF, which comprises Radix et Rhizoma Ginseng, Rhizoma Gastrodiae, Ramuli Euonymi, and Rhizoma Chuanxiong, has been reported to replenish Qi, remove blood stasis, and calm the latent yang of the liver. Ginsenosides Rg1, Rb1, gastrodin, quercetin, and ferulic acid are the main bioactive components in SMYZF \[[@B32]\].

Research has demonstrated that ginsenosides, which are the main components of Ginseng, have protective effects on the vascular endothelium \[[@B33]\]. Ginsenosides have been reported to promote nerve cell regeneration, halt the deterioration of dementia, and improve the capacity for learning and memory \[[@B19]\]. To some extent, ginsenoside Rb1 could improve vascular endothelial function by improving inflammation, reducing oxidative stress, and increasing NO synthesis. Moreover, ginsenosides Rb1 and Rg1 have been reported to protect vascular endothelial cells from oxygen-glucose deprivation/reoxygenation injury and to promote nerve cell regeneration. Furthermore, they have been reported to interfere with the pathological dementia process and improve learning and memory \[[@B34], [@B35]\]. Gastrodin has been shown to increase the activity of cerebral microvascular endothelial cells after ischemic injury \[[@B36]\]. It can maintain the vasoconstriction balance by affecting the secretion of vasoconstrictive ET-1 by vascular endothelial cells \[[@B37]\]. Gastrodin regulates vasomotor and neurotransmitter functions, improves the blood supply of the nervous system, and prevents cerebral ischemia, inflammation, and amyloid protein injury, thus protecting nerve cells \[[@B36], [@B38]\]. Increasing NO levels and decreasing ET levels could exert a protective effect on vascular endothelial function \[[@B15], [@B39]\]. Previous experimental findings in murine studies have indicated that Ramuli Euonymi could improve hypoxia tolerance, relieve vasospasm, and repair damaged vascular endothelium \[[@B40]\]. Ligustrazine induces microvessel dilation and increases blood flow, which is beneficial to the secretion of vasoactive substances by vascular endothelial cells. Rhizoma Chuanxiong promotes the proliferation of microvascular endothelial cells and microvessels and promotes angiogenesis \[[@B41]\]. Previous experimental studies have reported that Rhizoma Chuanxiong could affect the apoptosis signal transduction system downstream of caspase and inhibit apoptosis of vascular endothelial cells by regulating Bcl-2 and caspase-3 gene expression \[[@B42]\]. Ferulic acid inhibits platelet aggregation and thromboxane release and has an antithrombotic effect. Ferulic acid also scavenges free radicals, regulates nerve cell homeostasis, and protects nerve cells. Hence, these characteristics of the active ingredients of SMYZF may underlie the positive effects noted in patients with VaD.

The MMSE is used worldwide to assess cognitive function \[[@B43]\], with higher MMSE scores indicating better cognitive function. We used the MMSE to assess orientation ability (time orientation, spatial orientation, and calculation), memory (immediate memory and delayed memory), linguistic ability (naming, comprehension, and retelling), comprehension, attention, and calculation ability. We found a posttreatment improvement in the aforementioned domains in both groups. Furthermore, the SMYZF group showed a significant improvement in retelling, linguistic comprehension, and delayed memory abilities compared with the Ginkgo group. These findings indicate that SMYZF could improve cognitive function in patients with VaD.

ET and NO play a crucial role in vasomotor functions. Currently, ET-1 is the most potent vasoconstrictor known, while NO is the most potent endogenous vasodilator \[[@B36], [@B39]\]. Many studies have reported a positive association between ET-1 levels and vascular cognitive impairment severity \[[@B44], [@B45]\]. ET-1-induced vasoconstriction causes lumen stenosis, cerebral ischemia, and hypoxia, which promote the development of dementia, which is closely associated with cognitive impairment \[[@B39]\]. Previous studies have reported that patients with VaD have significantly lower serum NO levels and impaired vascular endothelial function compared to healthy individuals, which negatively affects VaD prognosis. In this study, we found a significant posttreatment increase in the serum NO levels and decrease in the serum ET-1 levels; and these posttreatment changes were more significant in the SMYZF group.

These findings indicate that SMYZF combined with Ginkgo extract tablets could significantly improve cognitive function and reduce cognitive decline symptoms in patients with VaD. Moreover, the underlying mechanism might be related to the improvement of vascular endothelial function and the restoration of normal vasomotor state. We found a significant posttreatment increase in serum VEGF levels in both groups and a significant decrease in the serum vWF levels in the SMYZF group. VEGF can directly act on vascular endothelial cytokines, effectively enhancing small blood vessel permeability and promoting the metastasis of endothelial cells and stromal cells. Furthermore, high VEGF expression can alleviate neuronal injury caused by ischemia and hypoxia \[[@B46], [@B47]\]. vWF is a marker for endothelial cell injury and dysfunction \[[@B48]\]. More severe endothelial cell injury is associated with lower vWF levels in endothelial cell cytoplasm and higher serum vWF levels. Our finding of posttreatment increases in serum VEGF levels indicates the promotion of cerebral microvascular regeneration or inhibition of NO-mediated vascular endothelial cell secretion of ET and vWF, as well as improvement of the hypoxic state of brain tissue and cognitive function in patients with VaD. Our study findings thus indicate that SMYZF combined with Ginkgo extract tablets could attenuate vascular endothelial cell dysfunction in patients with VaD.

NSE and BDNF can regulate the growth, development, and regeneration of the nervous system. NSE is highly specific for nerves, and previous studies have reported a significant negative correlation between serum NSE levels and poststroke MMSE scores. NSE might be involved in the regulation of neuronal regeneration \[[@B49]\]. BDNF might improve learning and memory in the pathological state \[[@B50]\], which could play an important role in VaD pathogenesis and development. We found a significant posttreatment decrease in serum NSE levels and a significant increase in serum BDNF levels in both groups, with a greater improvement in the SMYZF group. The NIHSS is used to evaluate neurological function. There were significantly lower posttreatment NIHSS scores in the SMYZF group compared with the Ginkgo group in our study. Patients with VaD often present with decreased ADL. We found a significant posttreatment decrease in the ADL scores in both groups. These findings indicate that SMYZF combined with Ginkgo extract tablets improved neurological function of patients with VaD more than the Ginkgo extract tablets alone, and this effect may be related to vascular endothelium function improvement.

The etiology and pathogenesis of VaD is complex and is closely related to various cardiovascular and cerebrovascular diseases. In the early and middle stages of VaD, there is accompanying cognitive decline, such as memory and intelligence decline, as well as personality changes, such as restlessness, irritability, and neurological impairment. We found that the SMYZF group had lower posttreatment total CM-SS scores compared with the Ginkgo group. Furthermore, the SMYZF group exhibited significant improvement in the symptoms of mental retardation, restlessness, irritability, and lip cyanosis compared with the Ginkgo group. This demonstrates a significant clinical effect of SMYZF combined with Ginkgo extract tablets for improving the TCM syndromes of patients with VaD; these effects may be related to the improvement of vascular endothelial and cognitive function, as well as neurological function and protection of neurons.

This study had several limitations. First, the study area was limited to Yanqing, Beijing, which limits the generalizability of the findings to other regions. Second, the study participants were middle-aged and elderly and with lower education and economic levels, which might have affected the NIHSS and ADL scale scores. Finally, the use of multiple evaluators may have resulted in subjective differences.

5. Conclusion {#sec5}
=============

SMYZF combined with Ginkgo extract tablets could improve vascular endothelial function, which might help improve cognitive and neurological functions in patients with VaD. Furthermore, these treatments can repair damaged nerves and improve symptoms of TCM syndrome in patients with mild-to-moderate VaD.
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###### 

Patients\' baseline characteristics.

                               SMYZF group (*n* = 85)   Ginkgo group (*n* = 87)   *P* value
  ---------------------------- ------------------------ ------------------------- -----------
  Age, years, mean (SD)        67.22 (7.12)             68.07 (6.83)              0.428
  Sex, *n* (%)                                                                    0.359
   Male                        39 (46)                  46 (53)                    
   Female                      46 (54)                  41 (47)                    
  Education level, *n* (%)                                                        0.842
   Below primary               7 (8)                    8 (9)                      
   Primary                     36 (42)                  42 (48)                    
   Middle school               41 (48)                  36 (41)                    
   High school or above        1 (1)                    1 (1)                      
  BMI, kg/m^2^, mean (SD)      25.00 (3.57)             24.63 (3.34)              0.484
  Heart rates, median (IQR)    70 (64--76)              70 (65--76)               0.510
  Risk factors, *n* (%)                                                            
   Hypertension                71 (84)                  72 (83)                   0.893
   Diabetes                    27 (32)                  23 (26)                   0.442
   Hyperlipidemia              19 (22)                  14 (16)                   0.297
   Coronary artery disease     9 (11)                   13 (15)                   0.393
  Scale scores, median (IQR)                                                       
   HAMD                        5 (3--6)                 5 (3--6)                  0.820
   HIS                         9 (8--9)                 8 (7--10)                 0.300
   CDR                         1 (1--1)                 1 (1--1)                  0.977
   NIHSS                       6 (5--7)                 6 (5--8)                  0.315
   ADL                         24 (21--33.5)            24 (21--29)               0.666

Note: sex, education level, hypertension, diabetes, hyperlipidemia, and coronary heart disease history were analyzed by chi-square test (*χ*^2^ test).

###### 

Comparison of MMSE and NIHSS scores after treatment in the 2 groups (*n*%).

  Scale   *n*            Group         Control cases (%)   Obvious effect cases (%)   Effectiveness cases (%)   Ineffectiveness cases (%)   Total effective cases (%)   *P* value
  ------- -------------- ------------- ------------------- -------------------------- ------------------------- --------------------------- --------------------------- ------------
  MMSE    85             SMYZF group   2                   6                          34                        42                          49.4                        0.041^*∗*^
  87      Ginkgo group   0             4                   26                         56                        34.5                                                    
  NIHSS   85             SMYZF group   0                   1                          75                        9                           89.41                       0.040^*∗*^
  87      Ginkgo group   0             5                   51                         31                        64.37                                                   

^*∗*^Significant effect (*P* \< 0.05).

###### 

Comparison of the MMSE before and after treatment in the 2 groups.

                               SMYZF group (*n* = 85), median (IQR)   Ginkgo group (*n* = 87), median (IQR)   *P* value
  ---------------------------- -------------------------------------- --------------------------------------- --------------
  Total scores                                                                                                 
   Before treatment            20 (17--21.5)                          20 (17--22)                             0.955
   After treatment             24 (21--26)                            23 (18--26)                             0.048^*∗*^
  Orientation ability                                                                                          
   Time orientation                                                                                            
    Before treatment           4 (3--5)                               4 (3--5)                                0.162
    After treatment            4 (3--5)                               4 (4--5)                                0.547
   Spatial orientation                                                                                         
    Before treatment           5 (5--5)                               5 (5--5)                                0.561
    After treatment            5 (5--5)                               5 (5--5)                                0.849
  Memory ability                                                                                               
   Immediate memory                                                                                            
    Before treatment           3 (2--3)                               3 (2--3)                                0.956
    After treatment            3 (3--3)                               3 (3--3)                                0.680
  Delayed recall                                                                                               
    Before treatment           0 (0--2)                               0 (0--1)                                0.127
    After treatment            2 (0--2)                               1 (0--2)                                0.046^*∗*^
  Linguistic ability                                                                                           
   Naming                                                                                                      
    Before treatment           2 (2--2)                               2 (2--2)                                0.312
    After treatment            2 (2--2)                               2 (2--2)                                \>0.999
   Retelling                                                                                                   
    Before treatment           0 (0--1)                               0 (0--0)                                0.182
    After treatment            1 (1--1)                               1 (0--1)                                0.001^*∗*^
   Comprehension                                                                                               
    Before treatment           2 (1--3)                               2 (1--3)                                0.941
    After treatment            3 (3--3)                               3 (2--3)                                \<0.001^*∗*^
   Attention and calculation                                                                                   
    Before treatment           2 (1--3)                               2 (1--4)                                0.302
    After treatment            3 (1--4)                               3 (1--4)                                0.954

^*∗*^Significant effect (*P*\<0.05).

###### 

Comparison of ET-1, NO, VEGF, and vWF before and after treatment.

                      SMYZF group (*n* = 85), median (IQR)   Ginkgo group (*n* = 87), median (IQR)   *P* value
  ------------------- -------------------------------------- --------------------------------------- ------------
  ET-1 (pg/mL)                                                                                        
   Before treatment   48.73 (24.86--96.48)                   56.20 (31.22--146.48)                   0.271
   After treatment    22.04 (8.79--61.19)                    30.85 (17.63--67.73)                    0.043^*∗*^
  NO (*μ*mol/L)                                                                                       
   Before treatment   16.06 (9.72--25.40)                    15.14 (8.94--24.01)                     0.614
   After treatment    20.30 (11.26--36.82)                   15.65 (9.04--26.86)                     0.040^*∗*^
  VEGF (pg/mL)                                                                                        
   Before treatment   128.37 (76.14--216.21)                 130.99 (56.13--189.34)                  0.207
   After treatment    301.47 (187.20--447.45)                308.16 (196.57--477.22)                 0.491
  vWF (ng/mL)                                                                                         
   Before treatment   11643.45 (6466.81--15808.98)           9676.81 (6391.48--14450.25)             0.193
   After treatment    9722.73 (6176.22--14078.82)            8913.02 (6278.56--13478.81)             0.385

^*∗*^Significant effect (*P*\<0.05).

###### 

Comparison of NSE, BDNF, and Hcy in the 2 groups before and after treatment.

                      SMYZF group (*n* = 85), median (IQR)   Ginkgo group (*n* = 87), median (IQR)   *P* value
  ------------------- -------------------------------------- --------------------------------------- ------------
  NSE                                                                                                 
   Before treatment   7.42 (5.97--10.06)                     7.75 (6.14--9.96)                       0.877
   After treatment    5.20 (4.23--6.08)                      5.93 (4.65--7.55)                       0.030^*∗*^
  BDNF                                                                                                
   Before treatment   22.88 (14.79--32.70)                   26.02 (17.52--32.86)                    0.389
   After treatment    38.79 (34.59--45.06)                   35.78 (29.72--44.29)                    0.026^*∗*^
  Hcy                                                                                                 
   Before treatment   8.87 (6.08--14.63)                     9.62 (6.36--15.01)                      0.595
   After treatment    6.58 (4.83--9.95)                      6.76 (3.89--12.5)                       0.995

^*∗*^Significant effect (*P* \< 0.05).

###### 

Comparison of CM-SS scores in the 2 groups before and after treatment.

  Symptom                                        SMYZF group (*n* = 85), median (IQR)   Ginkgo group (*n* = 87), median (IQR)   *P* value
  ---------------------------------------------- -------------------------------------- --------------------------------------- ------------
  Intelligence decline                                                                                                           
   Before treatment                              3 (3--6)                               3 (3--6)                                0.419
   After treatment                               0 (0--3)                               3 (0--6)                                0.006^*∗*^
  Soreness and weakness of the waist and knees                                                                                   
   Before treatment                              4 (2--4)                               4 (2--4)                                0.970
   After treatment                               2 (0--4)                               2 (0--4)                                0.570
  Restlessness                                                                                                                   
   Before treatment                              1 (0--2)                               1 (0--2)                                0.509
   After treatment                               0 (0--1)                               1 (1--2)                                \<0.001
  Rigid and silent                                                                                                               
   Before treatment                              0 (0--2)                               0 (0--2)                                0.792
   After treatment                               0 (0--2)                               0 (0--0)                                0.088
  Spasm and numb of limbs                                                                                                        
   Before treatment                              1 (1--1)                               1 (0--1)                                0.531
   After treatment                               1 (0--1)                               1 (0--1)                                0.077
  Cardiopalmus                                                                                                                   
   Before treatment                              1 (0--2)                               1 (0--1)                                0.890
   After treatment                               0 (0--1)                               0 (0--1)                                0.909
  Irritability                                                                                                                   
   Before treatment                              1 (0--1)                               1 (0--1)                                0.380
   After treatment                               0 (0--1)                               0 (0--2)                                0.001^*∗*^
  Dry skin                                                                                                                       
   Before treatment                              0 (0--1)                               0 (0--1)                                0.615
   After treatment                               0 (0--1)                               0 (0--1)                                0.927
  Cyanosis of the lips                                                                                                           
   Before treatment                              1 (1--2)                               1 (1--2)                                0.948
   After treatment                               1 (0--1)                               1 (0--2)                                0.013^*∗*^
  Enuresis nocturna                                                                                                              
   Before treatment                              2 (1--2)                               2 (1--2)                                0.071
   After treatment                               2 (0.5--2)                             2 (1--2)                                0.713
  Tinnitus                                                                                                                       
   Before treatment                              1 (0--2)                               1 (0--3)                                0.166
   After treatment                               1 (0--1)                               1 (0--2)                                0.735
  Total scores                                                                                                                   
   Before treatment                              17 (11--20)                            16 (11--21)                             0.844
   After treatment                               10 (6--13)                             11 (7--18)                              0.033^*∗*^

^*∗*^Significant effect (*P* \< 0.05).

[^1]: Academic Editor: Patricia Valentao
